



# Correction: High-risk neuroblastoma stage 4 (NBS4): multi-target inhibitors for c-Src kinases (Csk) and retinoic acid (RA) signalling pathways

Amgad Gerges<sup>1\*</sup> , Una Canning<sup>2</sup>

<sup>1</sup>Bioscience Department, School of Human Sciences, London Metropolitan University, N7 8DB London, United Kingdom

<sup>2</sup>Independent Scholar, SE4 1JT London, United Kingdom

**\*Correspondence:** Amgad Gerges, Bioscience Department, School of Human Sciences, London Metropolitan University, N7 8DB London, United Kingdom. [a.gerges@londonmet.ac.uk](mailto:a.gerges@londonmet.ac.uk)


**Published:** January 9, 2026

**Cite this article:** Gerges A, Canning U. Correction: High-risk neuroblastoma stage 4 (NBS4): multi-target inhibitors for c-Src kinases (Csk) and retinoic acid (RA) signalling pathways. *Explor Drug Sci.* 2026;4:1008142. <https://doi.org/10.37349/eds.2026.1008142>

Correction to “High-risk neuroblastoma stage 4 (NBS4): multi-target inhibitors for c-Src kinases (Csk) and retinoic acid (RA) signalling pathways” by Gerges A and Canning U. *Explor Drug Sci.* 2025;3:1008109. DOI: [10.37349/eds.2025.1008109](https://doi.org/10.37349/eds.2025.1008109)

The authors have recognized an error in the published paper:

In [Figure 12](#), the cluster label shown within the synthesis route box was incorrectly presented as “Cluster 4, 1 of 25”. The correct label should read “Cluster 4, 1 of 1”. The corrected version of the figure is provided below.



**Figure 12. Synthesis of cluster 4, 1 of 1, c-Src inhibitor**



This correction does not affect the scientific content, interpretation of the results, or the conclusions of the paper. The authors apologize for any inconvenience caused to the readers by this error.

The original uncorrected PDF can be accessed from [https://www.explorationpub.com/uploads/1008109\\_1st.pdf](https://www.explorationpub.com/uploads/1008109_1st.pdf)